SG10202106830VA - Anti-cd137 antigen-binding molecule and utilization thereof - Google Patents

Anti-cd137 antigen-binding molecule and utilization thereof

Info

Publication number
SG10202106830VA
SG10202106830VA SG10202106830VA SG10202106830VA SG10202106830VA SG 10202106830V A SG10202106830V A SG 10202106830VA SG 10202106830V A SG10202106830V A SG 10202106830VA SG 10202106830V A SG10202106830V A SG 10202106830VA SG 10202106830V A SG10202106830V A SG 10202106830VA
Authority
SG
Singapore
Prior art keywords
antigen
utilization
binding molecule
molecule
binding
Prior art date
Application number
SG10202106830VA
Other languages
English (en)
Inventor
Tomoyuki Igawa
Mika Sakurai
Shun Shimizu
Yuji Hori
Naoka Hironiwa
Nasa Savory
Yoshinori Narita
Takayuki Kamikawa
Taro Miyazaki
Shojiro Kadono
Masami Hasegawa
Kanako Tatsumi
Akira Hayasaka
Takeaki Kawai
Futa Mimoto
Hiroki Kawauchi
Masaki Kamimura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10202106830VA publication Critical patent/SG10202106830VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10202106830VA 2018-08-10 2019-08-09 Anti-cd137 antigen-binding molecule and utilization thereof SG10202106830VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018152126 2018-08-10

Publications (1)

Publication Number Publication Date
SG10202106830VA true SG10202106830VA (en) 2021-08-30

Family

ID=69415566

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202106830VA SG10202106830VA (en) 2018-08-10 2019-08-09 Anti-cd137 antigen-binding molecule and utilization thereof
SG11202003531WA SG11202003531WA (en) 2018-08-10 2019-08-09 Anti-cd137 antigen-binding molecule and utilization thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202003531WA SG11202003531WA (en) 2018-08-10 2019-08-09 Anti-cd137 antigen-binding molecule and utilization thereof

Country Status (21)

Country Link
US (2) US12304960B2 (he)
EP (1) EP3835321A4 (he)
JP (4) JP6718560B1 (he)
KR (2) KR102259473B1 (he)
CN (3) CN118754986A (he)
AR (1) AR114550A1 (he)
AU (1) AU2019318031B2 (he)
BR (1) BR112021002037A2 (he)
CA (1) CA3108369A1 (he)
CL (3) CL2021000327A1 (he)
CO (1) CO2021003098A2 (he)
CR (1) CR20210127A (he)
EA (1) EA202190451A1 (he)
IL (2) IL280720B2 (he)
MX (1) MX2021001431A (he)
PE (1) PE20210343A1 (he)
PH (1) PH12021500011A1 (he)
SG (2) SG10202106830VA (he)
TW (3) TWI852243B (he)
UA (1) UA128584C2 (he)
WO (1) WO2020032230A1 (he)

Families Citing this family (12)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
MX352889B (es) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
WO2013180200A1 (ja) 2012-05-30 2013-12-05 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆจ™็š„็ต„็น”็‰น็•ฐ็š„ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
CN105246914B (zh) 2013-04-02 2021-08-27 ไธญๅค–ๅˆถ่ฏๆ ชๅผไผš็คพ FcๅŒบๅ˜ไฝ“
DK3078744T3 (da) 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
KR102259473B1 (ko) * 2018-08-10 2021-06-02 ์ถ”๊ฐ€์ด ์„ธ์ด์•ผ์ฟ  ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ํ•ญcd137 ํ•ญ์› ๊ฒฐํ•ฉ ๋ถ„์ž ๋ฐ ๊ทธ์˜ ์‚ฌ์šฉ
CN119264211A (zh) 2018-08-27 2025-01-07 ็‘žๆณฝๆฉๅˆถ่ฏๅ…ฌๅธ ๆ‹‰ๆ›ผๅ…‰่ฐฑๅœจไธ‹ๆธธ็บฏๅŒ–ไธญ็š„ๅบ”็”จ
UA128549C2 (uk) * 2019-12-27 2024-08-07 ะงัƒะณะฐั– ะกะตะนัะบัƒ ะšะฐะฑัƒัั–ะบั– ะšะฐะนัั ะะฝั‚ะธั‚ั–ะปะพ ะดะพ ctla-4 ั‚ะฐ ะนะพะณะพ ะทะฐัั‚ะพััƒะฒะฐะฝะฝั
TWI895351B (zh) * 2020-02-12 2025-09-01 ๆ—ฅๅ•†ไธญๅค–่ฃฝ่—ฅ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็”จๆ–ผ็™Œ็—‡ไน‹ๆฒป็™‚็š„ๆŠ—cd137ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
CN115605228A (zh) * 2020-04-17 2023-01-13 ่‹ๅทžไธๅญš้ถ็‚น็”Ÿ็‰ฉๆŠ€ๆœฏๆœ‰้™ๅ…ฌๅธ๏ผˆCn๏ผ‰ ไธ€็ง็‰นๅผ‚ๆ€ง็ป“ๅˆcd137็š„ๅˆถๅ‰‚ๅŠๅ…ถ็”จ้€”
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
AR126220A1 (es) * 2021-06-25 2023-09-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
WO2025141786A1 (ja) * 2023-12-27 2025-07-03 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆŠ—ไฝ“ใฎ่ฃฝ้€ ๆ–นๆณ•

Family Cites Families (259)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 ใ‚จใ‚นใƒปใƒ“ใ‚ฃใƒป๏ผ’ใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๅค‰ๆ€งๆŠ—ไฝ“ใฎใ€ใพใŸใฏๅค‰ๆ€งๆŠ—ไฝ“ใซ้–ขใ™ใ‚‹ๆ”น่‰ฏ
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmรค ja kรคyttรถmenete lmรค
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimรฆriske og radioaktivt mรฆrkede antistoffer mod humant B-lymfocytbegrรฆnset differentieringsantig
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procรฉdรฉ de traitement de rรฉsidus de combustion et installation de mise en ร“oeuvre dudit procรฉdรฉ.
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5998588A (en) 1995-09-01 1999-12-07 University Of Washington Interactive molecular conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP4046354B2 (ja) 1996-03-18 2008-02-13 ใƒœใƒผใƒ‰ ใ‚ชใƒ– ใƒชใƒผใ‚ธใ‚งใƒณใƒ„๏ผŒใ‚ถ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใƒ†ใ‚ญใ‚ตใ‚น ใ‚ทใ‚นใƒ†ใƒ  ๅข—ๅคงใ—ใŸๅŠๆธ›ๆœŸใ‚’ๆœ‰ใ™ใ‚‹ๅ…็–ซใ‚ฐใƒญใƒ–ใƒชใƒณๆง˜ใƒ‰ใƒกใ‚คใƒณ
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikรถrper varianten und fragmente davon
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhรฆngig cellulรฆr cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
RU2236222C2 (ru) 1998-09-11 2004-09-20 ะะนะปะตะบััƒั ะŸั‚ะธ ะ›ะธะผะธั‚ะตะด ะœะพะดัƒะปัั‚ะพั€ั‹ fc-ั€ะตั†ะตะฟั‚ะพั€ะฐ ะธ ะธั… ะฟั€ะธะผะตะฝะตะฝะธะต
WO2000015214A1 (en) 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciaล‚o, komรณrka gospodarza, sposรณb wytwarzania przeciwciaล‚a oraz zastosowanie przeciwciaล‚a
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6635422B2 (en) 1999-12-28 2003-10-21 Ribonomics, Inc. Methods for isolating and characterizing endogenous mRNA-protein (mRNP) complexes
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EE200200538A (et) 2000-03-22 2004-04-15 Octagene Gmbh Rekombinantsete verehรผรผbimisfaktorite produtseerimine inimese rakuliinides
JP2003531588A (ja) 2000-04-11 2003-10-28 ใ‚ธใ‚งใƒใƒณใƒ†ใƒƒใ‚ฏใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒƒใƒ‰ ๅคšไพกๆŠ—ไฝ“ใจใใฎ็”จ้€”
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1332209B1 (en) 2000-09-08 2009-11-11 Universitรคt Zรผrich Collections of repeat proteins comprising repeat modules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20040001822A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Cรฉlulas das quais o genoma รฉ modificado
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivitรคt eines am gdp-fucosetransport beteiligten proteins
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcฮณRIIB specific antibodies and methods of use thereof
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
RU2390527C2 (ru) 2002-09-27 2010-05-27 ะšัะตะฝะบะพั€, ะ˜ะฝะบ. ะะะขะ˜ะขะ•ะ›ะž, ะกะžะ”ะ•ะ ะ–ะะฉะ•ะ• Fc-ะ’ะะ ะ˜ะะะขะะฃะฎ ะงะะกะขะฌ (ะ’ะะ ะ˜ะะะขะซ), ะคะะ ะœะะฆะ•ะ’ะขะ˜ะงะ•ะกะšะะฏ ะšะžะœะŸะžะ—ะ˜ะฆะ˜ะฏ, ะกะžะ”ะ•ะ ะ–ะะฉะะฏ ะะะขะ˜ะขะ•ะ›ะž, ะ˜ ะกะŸะžะกะžะ‘ ะ›ะ•ะงะ•ะะ˜ะฏ ะœะ›ะ•ะšะžะŸะ˜ะขะะฎะฉะ•ะ“ะž
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
RU2337107C2 (ru) 2003-05-02 2008-10-27 ะšัะตะฝะบะพั€, ะ˜ะฝะบ. ะžะŸะขะ˜ะœะ˜ะ—ะ˜ะ ะžะ’ะะะะซะ• Fc-ะ’ะะ ะ˜ะะะขะซ, ะ˜ะœะ•ะฎะฉะ˜ะ• ะ˜ะ—ะœะ•ะะ•ะะะžะ• ะกะ’ะฏะ—ะซะ’ะะะ˜ะ• ะก FcฮณR, ะ˜ ะกะŸะžะกะžะ‘ะซ ะ˜ะฅ ะŸะžะ›ะฃะงะ•ะะ˜ะฏ
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 ๅ”ๅ’Œ้†—้…ตๅทฅๆฅญๆ ชๅผไผš็คพ ่žๅˆ่›‹็™ฝ่ณช็ต„ๆˆ็‰ฉ
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 ๅ”ๅ’Œ้†—้…ตๅทฅๆฅญๆ ชๅผไผš็คพ ฮฑ๏ผ‘๏ผŒ๏ผ–โˆ’ใƒ•ใ‚ณใ‚ทใƒซใƒˆใƒฉใƒณใ‚นใƒ•ใ‚งใƒฉใƒผใ‚ผใฎๆฉŸ่ƒฝใ‚’ๆŠ‘ๅˆถใ™ใ‚‹๏ผฒ๏ผฎ๏ผกใ‚’็”จใ„ใŸๆŠ—ไฝ“็ต„ๆˆ็‰ฉใฎ่ฃฝ้€ ๆณ•
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1701979A2 (en) 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. ๆŠ—ไฝ“็ต„ๆˆ็‰ฉใ‚’ๅซๆœ‰ใ™ใ‚‹ๅŒป่–ฌ
KR101225299B1 (ko) 2003-12-10 2013-01-24 ๋ฉ”๋‹ค๋ ‰์Šค, ์ธ์ฝ”ํฌ๋ ˆ์ดํ‹ฐ๋“œ ์ธํ„ฐํŽ˜๋ก  ์•ŒํŒŒ ํ•ญ์ฒด ๋ฐ ๊ทธ์˜ ์šฉ๋„
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP2005292087A (ja) 2004-04-05 2005-10-20 Shionogi & Co Ltd ๏ผ•โ€™โˆ’ใƒ‡ใ‚ชใ‚ญใ‚ทโˆ’๏ผ•โ€™โˆ’ใƒกใƒใƒซใƒใ‚ชใ‚ขใƒ‡ใƒŽใ‚ทใƒณใซๅฏพใ™ใ‚‹ๆŠ—ไฝ“
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
JP5367982B2 (ja) 2004-04-16 2013-12-11 ใƒžใ‚ฏใƒญใ‚ธใ‚งใƒ‹ใ‚ฏใ‚น๏ผŒใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒƒใƒ‰ ๏ผฆ๏ฝƒฮณ๏ผฒ๏ผฉ๏ผฉ๏ผข็‰น็•ฐ็š„ๆŠ—ไฝ“ใจใใฎๅˆฉ็”จๆณ•
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche ๆŠ—๏ฝ๏ฝ˜๏ผ”๏ผ๏ฝŒๆŠ—้ซ”
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc ู…ุฑูƒุจุงุช ุฃุฌุณุงู… ู…ุถุงุฏุฉ .
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CN101098890B (zh) 2004-11-12 2012-07-18 ่ตž็ง‘่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๅฏนFcRn็š„็ป“ๅˆ่ขซๆ”นๅ˜็š„Fcๅ˜ไฝ“
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2007022520A2 (en) 2005-08-19 2007-02-22 Cerus Corporation Antibody-mediated enhancement of immune response
KR20080073293A (ko) 2005-10-14 2008-08-08 ๋ฉ”๋””๋ฎจ ์—˜์—˜์”จ ํ•ญ์ฒด ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์˜ ์„ธํฌ ๋””์Šคํ”Œ๋ ˆ์ด
EP1954720A1 (en) 2005-10-31 2008-08-13 The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health Antibodies and immunotoxins that target human glycoprotein nmb
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipรฉptidos de uniรณn con secuencias hipervariables de VH/VL diversificadas y consenso
JP2009519236A (ja) 2005-11-30 2009-05-14 ใ‚ญใƒฃใƒณโˆ’ใƒ•ใ‚กใ‚คใƒˆใƒปใƒใ‚คใ‚ชใƒ•ใ‚กใƒผใƒžใƒปใƒชใƒŸใƒ†ใƒƒใƒ‰ ๏ผก๏ผ“ใ‚ขใƒ‡ใƒŽใ‚ทใƒณใƒฌใ‚ปใƒ—ใ‚ฟใƒผๆŠ—ไฝ“ใฎๆฒป็™‚็š„ไฝฟ็”จ
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
WO2008105886A2 (en) 2006-05-26 2008-09-04 Macrogenics, Inc. HUMANIZED FCฮณRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligaรงรฃo ao alvo variantes e suas utilizaรงรตes
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcฮณRactivating and FcฮณRinhibiting
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2125893A2 (en) 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008114011A2 (en) 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
CN100592373C (zh) 2007-05-25 2010-02-24 ็พคๅบท็ง‘ๆŠ€(ๆทฑๅœณ)ๆœ‰้™ๅ…ฌๅธ ๆถฒๆ™ถๆ˜พ็คบ้ขๆฟ้ฉฑๅŠจ่ฃ…็ฝฎๅŠๅ…ถ้ฉฑๅŠจๆ–นๆณ•
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de uniรณn de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de รกcido nucleico codificante; celula huesped que la comprende; composiciรณn farmaceutica; uso mรฉdico para tratar o prevenir una condiciรณn asociada con il-18r; mรฉtodo in vitro para inhibir la uniรณn de il-18 al il-18r.
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc ุจุฑูˆุชูŠู†ุงุช ู…ุฑุชุจุทุฉ ุจู…ูˆู„ุฏุงุช ู…ุถุงุฏุงุช ุชุชูุงุนู„ ู…ุน ุจุฑูˆุจุฑูˆุชูŠู† ูƒูˆู†ููŠุฑุชุงุฒ ุณูŠุชูŠู„ูŠุฒูŠู† ูƒูƒุณูŠู† ู…ู† ุงู„ู†ูˆุน 9 (pcsk9)
WO2009097017A2 (en) 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
CN101868246A (zh) 2007-09-21 2010-10-20 ๅŠ ๅˆฉ็ฆๅฐผไบšๅคงๅญฆ่‘ฃไบ‹ไผš ่ขซๅฏผ้ถ็š„ๅนฒๆ‰ฐ็ด ๆ˜พ็คบๅผบ็š„็ป†่ƒžๅ‡‹ไบกๅ’ŒๆŠ—่‚ฟ็˜คๆดปๆ€ง
KR101680906B1 (ko) 2007-09-26 2016-11-30 ์ถ”๊ฐ€์ด ์„ธ์ด์•ผ์ฟ  ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ํ•ญ์ฒด ์ •์ƒ์˜์—ญ ๊ฐœ๋ณ€์ฒด
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
KR100888133B1 (ko) 2007-10-02 2009-03-13 ์—์Šค์ผ€์ด์—๋„ˆ์ง€ ์ฃผ์‹ํšŒ์‚ฌ 4์ข…์˜ ๊ธˆ์†์„ฑ๋ถ„์œผ๋กœ ๊ตฌ์„ฑ๋œ ๋‹ค์„ฑ๋ถ„๊ณ„ ๋น„์Šค๋ฌด์Šค๋ชฐ๋ฆฌ๋ธŒ๋ฐ์ดํŠธ ์ด‰๋งค ์ œ์กฐ๋ฐฉ๋ฒ• ๋ฐ ์ƒ๊ธฐ์ด‰๋งค๋ฅผ ์ด์šฉํ•˜์—ฌ1,3-๋ถ€ํƒ€๋””์—”์„ ์ œ์กฐํ•˜๋Š” ๋ฐฉ๋ฒ•
WO2009062051A2 (en) 2007-11-08 2009-05-14 Pikamab, Inc. Methods and compositions for antibody therapy
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaรคล›ice s promijenjenim vezanjem na fcrn
JP6157046B2 (ja) 2008-01-07 2017-07-05 ใ‚ขใƒ ใ‚ธใ‚งใƒณ ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ้™้›ป็š„ใ‚นใƒ†ใ‚ขใƒชใƒณใ‚ฐ๏ผˆ๏ฝ…๏ฝŒ๏ฝ…๏ฝƒ๏ฝ”๏ฝ’๏ฝ๏ฝ“๏ฝ”๏ฝ๏ฝ”๏ฝ‰๏ฝƒ๏ฝ“๏ฝ”๏ฝ…๏ฝ…๏ฝ’๏ฝ‰๏ฝŽ๏ฝ‡๏ผ‰ๅŠนๆžœใ‚’็”จใ„ใŸๆŠ—ไฝ“๏ผฆ๏ฝƒใƒ˜ใƒ†ใƒญไบŒ้‡ไฝ“ๅˆ†ๅญใ‚’ไฝœ่ฃฝใ™ใ‚‹ใŸใ‚ใฎๆ–นๆณ•
CA2712432C (en) 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
KR102057826B1 (ko) 2008-04-11 2019-12-20 ์ถ”๊ฐ€์ด ์„ธ์ด์•ผ์ฟ  ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ๋ณต์ˆ˜ ๋ถ„์ž์˜ ํ•ญ์›์— ๋ฐ˜๋ณต ๊ฒฐํ•ฉํ•˜๋Š” ํ•ญ์› ๊ฒฐํ•ฉ ๋ถ„์ž
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2009155513A2 (en) 2008-06-20 2009-12-23 Novartis Ag Immunoglobulins with reduced aggregation
WO2010028791A1 (en) 2008-09-10 2010-03-18 Philochem Ag Display library for antibody selection
JP5913980B2 (ja) 2008-10-14 2016-05-11 ใ‚ธใ‚งใƒใƒณใƒ†ใƒƒใ‚ฏ๏ผŒ ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๅ…็–ซใ‚ฐใƒญใƒ–ใƒชใƒณๅค‰็•ฐไฝ“ๅŠใณใใฎ็”จ้€”
JP5807300B2 (ja) 2008-11-18 2015-11-10 ๆ ชๅผไผš็คพใ‚ทใƒŽใƒ†ใ‚นใƒˆ ่ฉฆๆ–™ไธญใฎ๏ฝƒๅๅฟœๆ€ง่›‹็™ฝ่ณชใฎๆธฌๅฎšๆ–นๆณ•ๅŠใณๆธฌๅฎš่ฉฆ่–ฌ
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma ุฃุฌุณุงู… ู…ุถุงุฏุฉ ุจุดุฑูŠุฉ ุนุงู„ูŠุฉ ุงู„ุชูุงุนู„ ุงู„ูƒูŠู…ุงูˆูŠ ุจุงู„ู†ุณุจุฉ ู„ุฅู†ุฒูŠู… ุณุจุชูŠู„ูŠุณูŠู† ูƒู†ูุฑุชูŠุฒ ุจุฑูˆุจุฑูˆุชูŠู† / ูƒูŠูƒุณูŠู† ู†ูˆุน 9 (pcsk9).
RU2636046C2 (ru) 2009-01-12 2017-11-17 ะกะฐะนั‚ะพะผะบั ะขะตั€ะฐะฟัŒัŽั‚ะธะบั, ะ˜ะฝะบ ะšะพะผะฟะพะทะธั†ะธะธ ะผะพะดะธั„ะธั†ะธั€ะพะฒะฐะฝะฝั‹ั… ะฐะฝั‚ะธั‚ะตะป, ัะฟะพัะพะฑั‹ ะธั… ะฟะพะปัƒั‡ะตะฝะธั ะธ ะฟั€ะธะผะตะฝะตะฝะธั
US8647829B2 (en) 2009-02-20 2014-02-11 General Electric Company Switchable affinity binders
CN102369296A (zh) 2009-03-09 2012-03-07 ็”Ÿ็‰ฉ่›‹็™ฝๆœ‰้™ๅ…ฌๅธ Mirac่›‹็™ฝ
JP5717624B2 (ja) 2009-03-19 2015-05-13 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆŠ—ไฝ“ๅฎšๅธธ้ ˜ๅŸŸๆ”นๅค‰ไฝ“
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
AR076508A1 (es) 2009-05-01 2011-06-15 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
CN102549016B (zh) 2009-06-30 2015-05-06 ็ ”็ฉถๅ‘ๅฑ•ๅŸบ้‡‘ไผš ๅ…็–ซ็ƒ่›‹็™ฝfcๅคš่‚ฝ
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
JP2011097869A (ja) 2009-11-05 2011-05-19 Japan Science & Technology Agency ๆŠ—ใƒ’ใƒˆใ‚ขใƒ‡ใƒŽใ‚ทใƒณ๏ผก๏ผ’๏ฝๅ—ๅฎนไฝ“ใƒขใƒŽใ‚ฏใƒญใƒผใƒŠใƒซๆŠ—ไฝ“
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
JP2011184418A (ja) 2010-03-11 2011-09-22 Tokyo Institute Of Technology ่ฆชๅ’Œๆ€งๅฏๅค‰ๆŠ—ไฝ“
JP5932670B2 (ja) 2010-03-11 2016-06-08 ใƒฉใ‚คใƒŠใƒƒใƒˆ ใƒ‹ใƒฅใƒผใƒญใ‚ตใ‚คใ‚จใƒณใ‚น ใ‚ณใƒผใƒใƒฌใ‚คใ‚ทใƒงใƒณ ๏ฝ๏ผจไพๅญ˜ๆ€งใฎๆŠ—ๅŽŸ็ตๅˆใ‚’ๆœ‰ใ™ใ‚‹ๆŠ—ไฝ“
TWI667257B (zh) 2010-03-30 2019-08-01 ไธญๅค–่ฃฝ่—ฅ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ไฟƒ้€ฒๆŠ—ๅŽŸๆถˆๅคฑไน‹ๅ…ทๆœ‰็ถ“ไฟฎ้ฃพ็š„๏ผฆ๏ฝƒ๏ผฒ๏ฝŽ่ฆชๅ’ŒๅŠ›ไน‹ๆŠ—้ซ”
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012132067A1 (ja) 2011-03-30 2012-10-04 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญใฎ่ก€ๆผฟไธญๆปž็•™ๆ€งใจๅ…็–ซๅŽŸๆ€งใ‚’ๆ”นๅค‰ใ™ใ‚‹ๆ–นๆณ•
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
TWI687439B (zh) 2011-06-30 2020-03-11 ไธญๅค–่ฃฝ่—ฅ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็•ฐๆบไบŒ่šๅŒ–ๅคš่ƒœ่‚ฝ
EP2752200B1 (en) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
KR102276528B1 (ko) 2011-09-30 2021-07-12 ์ถ”๊ฐ€์ด ์„ธ์ด์•ผ์ฟ  ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ์ด์˜จ ๋†๋„ ์˜์กด์„ฑ ๊ฒฐํ•ฉ ๋ถ„์ž ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ
TW201817744A (zh) 2011-09-30 2018-05-16 ๆ—ฅๅ•†ไธญๅค–่ฃฝ่—ฅ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๅ…ทๆœ‰ไฟƒ้€ฒๆŠ—ๅŽŸๆธ…้™คไน‹๏ผฆ๏ฝƒ๏ผฒ๏ฝŽ็ตๅˆๅŸŸ็š„ๆฒป็™‚ๆ€งๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
RU2014117505A (ru) 2011-09-30 2015-11-10 ะงัƒะณะฐะธ ะกะตะนัะบัƒ ะšะฐะฑัƒัะธะบะธ ะšะฐะนัั ะะฝั‚ะธะณะตะฝัะฒัะทั‹ะฒะฐัŽั‰ะฐั ะผะพะปะตะบัƒะปะฐ ะดะปั ัƒัะบะพั€ะตะฝะธั ัƒะดะฐะปะตะฝะธั ะฐะฝั‚ะธะณะตะฝะพะฒ
JP6322411B2 (ja) 2011-09-30 2018-05-09 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ่ค‡ๆ•ฐใฎ็”Ÿ็†ๆดปๆ€งใ‚’ๆœ‰ใ™ใ‚‹ๆŠ—ๅŽŸใฎๆถˆๅคฑใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
JP6271251B2 (ja) 2011-10-05 2018-01-31 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ็ณ–้Ž–ๅ—ๅฎนไฝ“็ตๅˆใƒ‰ใƒกใ‚คใƒณใ‚’ๅซใ‚€ๆŠ—ๅŽŸใฎ่ก€ๆผฟไธญใ‹ใ‚‰ใฎๆถˆๅคฑใ‚’ไฟƒ้€ฒใ™ใ‚‹ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
EP3738980A1 (en) 2012-02-24 2020-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI619729B (zh) 2012-04-02 2018-04-01 ๅ†็”Ÿๅ…ƒ้†ซ่—ฅๅ…ฌๅธ ๆŠ—๏ผ๏ฝˆ๏ฝŒ๏ฝ๏ผ๏ฝ‚*๏ผ’๏ผ—ๆŠ—้ซ”ๅŠๅ…ถ็”จ้€”
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆจ™็š„็ต„็น”็‰น็•ฐ็š„ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
JP6628966B2 (ja) 2012-06-14 2020-01-15 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆ”นๅค‰ใ•ใ‚ŒใŸ๏ผฆ๏ฝƒ้ ˜ๅŸŸใ‚’ๅซใ‚€ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcฮณriib-specific fc region variant
WO2014030750A1 (ja) 2012-08-24 2014-02-27 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ใƒžใ‚ฆใ‚นFcฮณRII็‰น็•ฐ็š„FcๆŠ—ไฝ“
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipรฉptido heterodimerizado
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma ุงู„ุฃุฌุณุงู… ุงู„ู…ุถุงุฏุฉ ู„ู…ุถุงุฏ ุงู†ุชุฑู„ูˆูƒูŠู†-33 ูˆุงุณุชุนู…ุงู„ุงุชู‡ุง
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EP2968985A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP2970497B1 (en) 2013-03-15 2017-10-25 Bayer HealthCare LLC Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
WO2014150983A2 (en) 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
AU2014230018B2 (en) 2013-03-15 2018-02-22 Affibody Ab New polypeptides
CN105246914B (zh) 2013-04-02 2021-08-27 ไธญๅค–ๅˆถ่ฏๆ ชๅผไผš็คพ FcๅŒบๅ˜ไฝ“
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
RU2019121863A (ru) 2013-09-18 2019-08-29 ะ ะตะณะตะฝะตั€ะพะฝ ะคะฐั€ะผะฐััŒัŽั‚ะธะบะฐะปะท, ะ˜ะฝะบ. ะะฝั‚ะธั‚ะตะปะฐ ัะพ ะฒัั‚ั€ะพะตะฝะฝั‹ะผ ะฒ ะปะตะณะบะธะต ั†ะตะฟะธ ะณะธัั‚ะธะดะธะฝะพะผ ะธ ะณะตะฝะตั‚ะธั‡ะตัะบะธ ะผะพะดะธั„ะธั†ะธั€ะพะฒะฐะฝะฝั‹ะต ะพั‚ะปะธั‡ะฝั‹ะต ะพั‚ ั‡ะตะปะพะฒะตะบะฐ ะถะธะฒะพั‚ะฝั‹ะต ะดะปั ะธั… ะฟะพะปัƒั‡ะตะฝะธั
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
WO2015077491A1 (en) 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
DK3078744T3 (da) * 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
ES2818800T3 (es) 2014-06-11 2021-04-14 Idac Theranostics Inc Mรฉtodo para reducir los efectos secundarios de un agente de control del punto de control inmunitario
KR101860280B1 (ko) 2014-12-19 2018-05-21 ์ถ”๊ฐ€์ด ์„ธ์ด์•ผ์ฟ  ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ํ•ญ-๋งˆ์ด์˜ค์Šคํƒ€ํ‹ด ํ•ญ์ฒด, ๋ณ€์ด์ฒด Fc ์˜์—ญ์„ ํ•จ์œ ํ•˜๋Š” ํด๋ฆฌํŽฉํƒ€์ด๋“œ, ๋ฐ ์‚ฌ์šฉ ๋ฐฉ๋ฒ•
CN108064176A (zh) 2015-04-22 2018-05-22 ๅบ“็‘ž็“ฆๆ ผ่‚กไปฝๅ…ฌๅธ ็”จไบŽๆฒป็–—่‚ฟ็˜ค็–พ็—…็š„ๅซๆœ‰rna็š„็ป„ๅˆ็‰ฉ
WO2016194992A1 (ja) * 2015-06-05 2016-12-08 ไธญๅค–่ฃฝ่–ฌๆ ชๅผไผš็คพ ๅ…็–ซๆดปๆ€งๅŒ–ๅ‰คใฎไฝต็”จ
UA120981C2 (uk) 2015-09-18 2020-03-10 ะงัƒะณะฐั– ะกะตะนัะบัƒ ะšะฐะฑัƒัั–ะบั– ะšะฐะนัั ะะฝั‚ะธั‚ั–ะปะพ, ั‰ะพ ะทะฒ'ัะทัƒั”ั‚ัŒัั ะท il-8, ั‚ะฐ ะนะพะณะพ ะทะฐัั‚ะพััƒะฒะฐะฝะฝั
EP3368567B1 (en) 2015-10-28 2025-10-01 Yale University Humanized anti-dkk2 antibody and uses thereof
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipรฉptidos que contienen regiones fc variantes asรญ como mรฉtodos de uso
WO2017205745A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
CN112210010B (zh) 2017-01-06 2023-12-05 ไผ˜็‰นๅŠ›ๅ…‹ๆ–ฏๆœ‰้™ๅ…ฌๅธ ๆŠ—-ไบบ4-1bbๆŠ—ไฝ“ๅŠๅ…ถๅบ”็”จ
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
CA3071383C (en) 2017-08-01 2022-04-12 Eli Lilly And Company Anti-cd137 antibodies
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
AU2018348431B2 (en) 2017-10-10 2025-10-02 Numab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
TWI701259B (zh) 2017-11-09 2020-08-11 ๅคง้™ธๅ•†ไธŠๆตทๆ‡ท่ถŠ็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ๏ผ”๏น˜๏ผ‘๏ฝ‚๏ฝ‚ๆŠ—้ซ”ๅŠๅ…ถ่ฃฝๅ‚™ๆ–นๆณ•ๅ’Œๆ‡‰็”จ
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
KR20200113228A (ko) 2018-01-22 2020-10-06 ์ง€์•™์ˆ˜ ํ—จ๊ทธ๋ฃจ์ด ๋ฉ”๋””์Šจ ์ปดํผ๋‹ˆ ๋ฆฌ๋ฏธํ‹ฐ๋“œ ํ•ญ-4-1bb ํ•ญ์ฒด, ์ด์˜ ํ•ญ์›-๊ฒฐํ•ฉ ๋‹จํŽธ ๋ฐ ์ด์˜ ์˜ํ•™์  ์šฉ๋„
JP7337099B2 (ja) 2018-05-25 2023-09-01 ใ‚ขใƒฌใ‚ฏใƒˆใƒซ ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ๆŠ—๏ฝ“๏ฝ‰๏ฝ’๏ฝ๏ฝๆŠ—ไฝ“ใŠใ‚ˆใณใใฎไฝฟ็”จๆณ•
PT3820569T (pt) 2018-07-12 2025-01-14 Invox Pharma Ltd Molรฉculas de anticorpo que se ligam a pd-l1 e cd137
KR102259473B1 (ko) 2018-08-10 2021-06-02 ์ถ”๊ฐ€์ด ์„ธ์ด์•ผ์ฟ  ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ํ•ญcd137 ํ•ญ์› ๊ฒฐํ•ฉ ๋ถ„์ž ๋ฐ ๊ทธ์˜ ์‚ฌ์šฉ
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH ANTIGEN-BINDING DOMAIN WITH VARIABLE BINDING ACTIVITY TO ANTIGEN DEPENDING ON MTA AND LIBRARY TO OBTAIN THE ANTIGEN-BINDING DOMAIN
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
TWI895351B (zh) 2020-02-12 2025-09-01 ๆ—ฅๅ•†ไธญๅค–่ฃฝ่—ฅ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็”จๆ–ผ็™Œ็—‡ไน‹ๆฒป็™‚็š„ๆŠ—cd137ๆŠ—ๅŽŸ็ตๅˆๅˆ†ๅญ

Also Published As

Publication number Publication date
JP2020146058A (ja) 2020-09-17
CR20210127A (es) 2021-04-19
WO2020032230A1 (ja) 2020-02-13
CA3108369A1 (en) 2020-02-13
TW202315892A (zh) 2023-04-16
IL280720B1 (he) 2024-12-01
JP6718560B1 (ja) 2020-07-08
EA202190451A1 (ru) 2021-07-13
IL317002A (he) 2025-01-01
IL280720A (he) 2021-03-25
JP2025138826A (ja) 2025-09-25
PH12021500011A1 (en) 2021-09-13
KR20200091340A (ko) 2020-07-30
EP3835321A4 (en) 2022-11-02
BR112021002037A2 (pt) 2021-05-04
JP7708911B2 (ja) 2025-07-15
IL280720B2 (he) 2025-04-01
CN118754986A (zh) 2024-10-11
TWI734166B (zh) 2021-07-21
CL2025001086A1 (es) 2025-06-06
CN118852438A (zh) 2024-10-29
US20250388689A1 (en) 2025-12-25
KR102259473B1 (ko) 2021-06-02
US12304960B2 (en) 2025-05-20
US20210324099A1 (en) 2021-10-21
CN112839960B (zh) 2024-09-06
AU2019318031B2 (en) 2025-06-05
CN112839960A (zh) 2021-05-25
UA128584C2 (uk) 2024-08-21
SG11202003531WA (en) 2020-05-28
JPWO2020032230A1 (ja) 2020-08-20
AU2019318031A1 (en) 2021-02-25
KR102697702B1 (ko) 2024-08-22
JP2024075633A (ja) 2024-06-04
CL2021000327A1 (es) 2021-07-23
AR114550A1 (es) 2020-09-16
KR20210065204A (ko) 2021-06-03
TW202028236A (zh) 2020-08-01
CL2022003595A1 (es) 2023-06-30
EP3835321A1 (en) 2021-06-16
MX2021001431A (es) 2021-05-12
TWI852243B (zh) 2024-08-11
PE20210343A1 (es) 2021-02-23
TW202138391A (zh) 2021-10-16
CO2021003098A2 (es) 2021-07-30
AU2019318031A8 (en) 2021-04-08
TWI792392B (zh) 2023-02-11

Similar Documents

Publication Publication Date Title
SG11202003531WA (en) Anti-cd137 antigen-binding molecule and utilization thereof
GB201811404D0 (en) Anti-CD137 Antibodies
ZA202001113B (en) Anti-cd137 molecules and use thereof
IL279321A (he) ื ื•ื’ื“ืŸ ื ื’ื“ SIRPalpha
IL282968A (he) ื ื•ื’ื“ื ื™ื ืœ- Anti - NKG2A ื•ื”ืฉื™ืžื•ืฉ ื‘ื”ื
IL276950A (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™- cd73 ื•ืฉื™ืžื•ืฉื™ื ื‘ื”ื
IL275737A (he) ื ื•ื’ื“ื ื™ื ื•ื•ืจื™ืื ื˜ื™ื ื ื’ื“ tigit
IL272349A (he) ื ื•ื’ื“ื ื™ anti-cd137
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL277559A (he) ื ื•ื’ื“ื ื™ื ืžื•ืœื˜ื™-ืกืคืฆื™ืคื™ื™ื ื•ืฉื™ืžื•ืฉ ื‘ื”ื
SG11202104240TA (en) Cll1-targeting antibody and application thereof
PT3505535T (pt) Anticorpo monoclonal anti-pd1, sua composiรงรฃo farmacรชutica e seu uso
IL275826A (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™-mct1 ื•ืฉื™ืžื•ืฉื™ื ืฉืœื”ื
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
AU201817419S (en) Handbag
IL280321A (he) ื ื•ื’ื“ื ื™ื ื ื’ื“ cxcr2 ื•ืฉื™ืžื•ืฉื™ื ืฉืœื”ื
IL278466B1 (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™-dll3 ื•ืฉื™ืžื•ืฉื™ื ื‘ื”ื
IL281202A (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™- tnfrsf9ื•ืฉื™ืžื•ืฉื™ื ื‘ื”ื
IL277075A (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™-phf-ื˜ืื• ื•ืฉื™ืžื•ืฉื™ื ื‘ื”ื
IL274502A (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™-ox40 ื•ืฉื™ืžื•ืฉื™ื ื‘ื”ื
SG11202100649VA (en) Anti-btla antibody
IL277330A (he) ื ื•ื’ื“ื ื™ื ืื ื˜ื™-il-27 ื•ืฉื™ืžื•ืฉื™ื ื‘ื”ื
IL276548A (he) ื ื•ื’ื“ื ื™ื ืงื•ืฉืจื™ โ€“ bcma ื•ืฉื™ืžื•ืฉื™ื ืฉืœื”ื
GB201811368D0 (en) Antibody
AU201817412S (en) Handbag